drugset / Trial / NCT05403723
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
NaSingle-groupOpen-labelTreatment
Summary
This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).
Timeline
- Start
- 2026-06-30
- Primary completion
- 2027-02
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Carboplatin | Small molecule | 6 unknown | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Etoposide | Small molecule | 80 mg/m2 | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |